ncRNA basic information
ncRNA ID:
MI0003166
ncRNA Database:
miRBase
ncRNA Name:
miR-520g
ncRNA Type:
miRNA
ncRNA Expression:
up-regulated
ncRNA Method:
qRT-PCR
ncRNA Target Gene:
DAPK2
ncRNA Pathway:
MAPK and AKT pathway
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00515 (APRD00359)
Drug Name:
Cisplatin
Drug Method:
In this study, we found that miR-520g expression gradually increased across normal, benign, borderline and EOC tissues. High miR-520g expression promoted tumor progression and chemoresistance to platinum-based chemotherapy, and reduced survival in EOC patients. miR-520g upregulation increased EOC cell proliferation, induced cell cycle transition and promoted cell invasion, while miR-520g downregulation inhibited tumor-related functions. In vivo, overexpression or downregulation of miR-520g respectively generated larger or smaller subcutaneous xenografts in nude mice. Death-associated protein kinase 2 (DAPK2) was a direct target of miR-520g. In 116 EOC tissue samples, miR-520g expression was significantly lower following DAPK2 overexpression. DAPK2 overexpression or miR-520g knockdown reduced EOC cell proliferation, invasion, wound healing and chemoresistance.
Drug Response:
resistant
Cancer basic information
Cancer:
epithelial ovarian cancer
Tissue/Cell:
tissue and cell line (A2780, SKOV3, OVA433, ES-2, OV2008, CaOV-3, MCAS, OVK18)
Other information
Title:
MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression.
Journal:
Oncotarget
Published:
2016
PubMed ID:
27049921